Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glatiramer acetate 40 mg three-times-weekly versus placebo in relapsing-remitting multiple sclerosis
2009-018084-27Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Glatiramer acetate 40 mg three times weekly with Placebo (2 arms). Primary endpoint: Total number of confirmed relapses during the placebo-controlled treatment phase. Started Mar 2010; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2009-018084-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018084-27.